| 1 |
Ahmadzadeh A, Seyedian SS, Valizadeh A, Soleimani M, Nazari P, Hamidi H. The Efficacy and Safety of Modified Docetaxel, Cisplatin, and 5-Fluorouracil Vs. Epirubicin, Oxaliplatin, and Capecitabine Regimen in the Advanced Gastric Cancer: A Randomized Controlled Clinical Trial. Asian Pac J Cancer Prev 2020;21:727-32. [PMID: 32212800 DOI: 10.31557/APJCP.2020.21.3.727] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 2 |
Petrelli F, Tomasello G, Ghidini M, Passalacqua R, Barni S. Modified schedules of DCF chemotherapy for advanced gastric cancer: a systematic review of efficacy and toxicity. Anticancer Drugs. 2017;28:133-141. [PMID: 27749286 DOI: 10.1097/cad.0000000000000436] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 3 |
Bozkaya Y, Doğan M, Yazıcı O, Erdem GU, Demirci NS, Zengin N. The efficacy of modified docetaxel-cisplatin-5-fluorouracil regimen as first-line treatment in patients with alpha-fetoprotein producing gastric carcinoma. Bosn J Basic Med Sci 2017;17:138-43. [PMID: 28273032 DOI: 10.17305/bjbms.2017.1684] [Reference Citation Analysis]
|
| 4 |
Maeda O, Matsuoka A, Miyahara R, Funasaka K, Hirooka Y, Fukaya M, Nagino M, Kodera Y, Goto H, Ando Y. Modified docetaxel, cisplatin and capecitabine for stage IV gastric cancer in Japanese patients: A feasibility study. World J Gastroenterol 2017; 23(6): 1090-1097 [PMID: 28246483 DOI: 10.3748/wjg.v23.i6.1090] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 5 |
Xie X, Wu Y, Luo Sh, Yang H, Li L, Zhou S, Shen R, Lin H. Efficacy and Toxicity of Low-Dose versus Conventional-Dose Chemotherapy for Malignant Tumors: a Meta-Analysis of 6 Randomized Controlled Trials. Asian Pac J Cancer Prev 2017;18:479-84. [PMID: 28345833 DOI: 10.22034/APJCP.2017.18.2.479] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
|
| 6 |
Wang J, Xu R, Li J, Bai Y, Liu T, Jiao S, Dai G, Xu J, Liu Y, Fan N, Shu Y, Ba Y, Ma D, Qin S, Zheng L, Chen W, Shen L. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer. Gastric Cancer 2016;19:234-44. [PMID: 25604851 DOI: 10.1007/s10120-015-0457-4] [Cited by in Crossref: 74] [Cited by in F6Publishing: 77] [Article Influence: 10.6] [Reference Citation Analysis]
|
| 7 |
Kalinka-Warzocha E, Plazas JG, Mineur L, Salek T, Hendlisz A, DeCosta L, Vogl FD, Passalacqua R. Chemotherapy treatment patterns and neutropenia management in gastric cancer. Gastric Cancer 2015;18:360-7. [PMID: 24792482 DOI: 10.1007/s10120-014-0375-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 8 |
Sendur MA, Ozdemir N, Özatlı T, Yazıcı O, Aksoy S, Ekinci AS, Yazılıtaş D, Günaydın Y, Oksuzoglu B, Benekli M, Zengin N. Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen. Med Oncol 2014;31:153. [PMID: 25099765 DOI: 10.1007/s12032-014-0153-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 9 |
Unek IT, Akman T, Oztop I, Unal OU, Salman T, Yilmaz U. Bimonthly regimen of high-dose leucovorin, infusional 5-fluorouracil, docetaxel, and cisplatin (modified DCF) in advanced gastric adenocarcinoma. Gastric Cancer 2013;16:428-34. [PMID: 23086560 DOI: 10.1007/s10120-012-0206-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 10 |
Jung JT. Chemotherapy of Advanced Gastric Cancer. Korean J Helicobacter Up Gastrointest Res 2013;13:142. [DOI: 10.7704/kjhugr.2013.13.3.142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 11 |
Unek IT, Akman T, Oztop I, Unal OU, Salman T, Yilmaz U. Bimonthly regimen of high-dose leucovorin, infusional 5-fluorouracil, docetaxel, and cisplatin (modified DCF) in advanced gastric adenocarcinoma. Gastric Cancer. 2013;16:428-434. [PMID: 23086560 DOI: 10.1007/s.10120-012-0206-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 12 |
Harada M, Iwata C, Saito H, Ishii K, Hayashi T, Yashiro M, Hirakawa K, Miyazono K, Kato Y, Kano MR. NC-6301, a polymeric micelle rationally optimized for effective release of docetaxel, is potent but is less toxic than native docetaxel in vivo. Int J Nanomedicine 2012;7:2713-27. [PMID: 22745540 DOI: 10.2147/IJN.S31247] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 13 |
Kos FT, Uncu D, Özdemir N, Budakoglu B, Odabaş H, Abali H, Oksuzoglu B, Aksoy S, Zengin N. Comparison of Cisplatin-5-Fluorouracil-Folinic Acid versus Modified Docetaxel-Cisplatin-5-Fluorouracil Regimens in the First-Line Treatment of Metastatic Gastric Cancer. Chemotherapy 2011;57:230-5. [DOI: 10.1159/000327840] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 14 |
Kim JA, Lee J, Han B, Park SH, Park JO, Park YS, Lim HY, Kang WK. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer. Cancer Chemother Pharmacol 2011;68:177-84. [PMID: 20878159 DOI: 10.1007/s00280-010-1452-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 15 |
Ma Y, Qin H, Zheng Q, Wang Y, Wang Z, Yang Z. Neoadjuvant chemotherapy with a combination of docetaxel, cisplatin, fluorouracil, and leucovorin in nonresectable advanced gastric cancer: a short communication. Med Oncol 2010;27:1089-95. [PMID: 19885749 DOI: 10.1007/s12032-009-9340-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
